Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?
- PMID: 22344941
- DOI: 10.1002/jnr.23011
Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?
Abstract
Autophagy plays a critical role in multiple pathological lesions of Alzheimer's disease (AD), such as the formation of amyloid plaques from amyloid-β (Aβ) production and accumulation via dysregulating amyloid precursor protein turnover and enhancing the activity of β- and/or γ-secretases, intraneuronal neurofibrillary tangles (NFT) because of tau hyperphosphorylation, and neuronal apoptosis. Dysfunction of the autophagy-lysosome system also contributes to Aβ accumulation and the formation of tau oligomers and insoluble aggregates, because induction of autophagy enhances the clearance of both soluble and aggregated forms of Aβ and tau proteins. The mammalian target of rapamycin (mTOR) pathway plays a central role in controlling protein homeostasis and negatively regulates autophagy. Inhibition of mTOR by rapamycin improves cognitive deficits and rescues Aβ pathology and NFTs by increasing autophagy. Several mTOR signaling components may be potential biomarkers of cognitive impairment in the clinical diagnosis of AD. Thus, mTOR-related agents through the control of autophagy-lysosome protein degradation are emerging as an important therapeutic target for AD.
Copyright © 2012 Wiley Periodicals, Inc.
Similar articles
-
Alteration of the Wnt/GSK3β/β‑catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer's disease model.Int J Mol Med. 2019 Jul;44(1):313-323. doi: 10.3892/ijmm.2019.4198. Epub 2019 May 15. Int J Mol Med. 2019. PMID: 31115485
-
mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.J Neurochem. 2005 Jul;94(1):215-25. doi: 10.1111/j.1471-4159.2005.03187.x. J Neurochem. 2005. PMID: 15953364
-
[Involvement of beta-amyloid in the etiology of Alzheimer's disease].Brain Nerve. 2010 Jul;62(7):691-9. Brain Nerve. 2010. PMID: 20675873 Review. Japanese.
-
Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.Acta Neuropathol. 2007 Jun;113(6):627-36. doi: 10.1007/s00401-007-0211-z. Epub 2007 Mar 13. Acta Neuropathol. 2007. PMID: 17431643
-
[Therapy of Alzheimer disease].Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Neuropsychopharmacol Hung. 2009. PMID: 19731816 Review. Hungarian.
Cited by
-
Autophagy modulation for Alzheimer's disease therapy.Mol Neurobiol. 2013 Dec;48(3):702-14. doi: 10.1007/s12035-013-8457-z. Epub 2013 Apr 27. Mol Neurobiol. 2013. PMID: 23625314 Review.
-
Investigating the Role of Spermidine in a Model System of Alzheimer's Disease Using Correlative Microscopy and Super-resolution Techniques.Front Cell Dev Biol. 2022 May 17;10:819571. doi: 10.3389/fcell.2022.819571. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35656544 Free PMC article.
-
Alzheimer's Disease and Cancer: When Two Monsters Cannot Be Together.Front Neurosci. 2019 Mar 1;13:155. doi: 10.3389/fnins.2019.00155. eCollection 2019. Front Neurosci. 2019. PMID: 30881282 Free PMC article.
-
Aerobic exercise attenuates autophagy-lysosomal flux deficits by ADRB2/β2-adrenergic receptor-mediated V-ATPase assembly factor VMA21 signaling in APP-PSEN1/PS1 mice.Autophagy. 2024 May;20(5):1015-1031. doi: 10.1080/15548627.2023.2281134. Epub 2023 Nov 15. Autophagy. 2024. PMID: 37964627 Free PMC article.
-
Phytoactive drugs used in the treatment of Alzheimer's disease and dementia.Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8633-8649. doi: 10.1007/s00210-024-03243-z. Epub 2024 Jun 28. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38940847 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
